Propanc Biopharma Advances Cancer Treatment with Key Updates

Propanc Biopharma, Inc. announced significant corporate developments and financial results for the first quarter of the fiscal year 2025/26, which ended on September 30, 2025. The biopharmaceutical company, based in Melbourne, Australia, is focused on creating innovative treatments for recurrent and metastatic cancer.

Clinical Advancements and Research Initiatives

One of the key highlights from Propanc’s update is the ongoing advancement of its lead candidate, PRP, which is on track to enter a Phase 1b clinical trial involving 30 to 40 patients with advanced solid tumors. This trial will take place at the esteemed Peter Mac Cancer Center in Melbourne, marking a world-first initiative. The company is currently engaged in good manufacturing practice (GMP) scale-up, validating analytical methods, and preparing necessary documentation for the clinical trial application. Notably, the purification processes have achieved over 95% purity, meeting pharmaceutical standards.

In addition, Propanc is progressing its fully synthetic recombinant version of PRP, known as Rec-PRP. This formulation is designed for enhanced stability and scalability, with research confirming methods for large-scale production. Patent drafting for this innovative approach is also underway, with formal preclinical development set to commence following necessary potency evaluations.

The company is also negotiating an extension of its joint research program, known as POP1, with the Universities of Jaén and Granada. Recent findings indicate that PRP significantly reduces tumorigenicity in Gemcitabine-resistant pancreatic cancer, suggesting potential for modulating malignant cells towards a less aggressive phenotype. Propanc plans to file additional patents based on these promising results.

Financial Performance and Strategic Developments

In terms of financial updates, Propanc successfully closed an underwritten public offering, selling 1,000,000 shares at $4.00 each, which raised gross proceeds of $4 million. Following this, the company’s common stock began trading on the Nasdaq Capital Market on August 15, 2025.

Additionally, Propanc secured a private placement agreement that allows for up to $100 million to accelerate its clinical development efforts. The company received an initial investment of $1 million through the issuance of 100 shares of Series C Convertible Preferred Stock, with expectations that this financing will support ongoing R&D activities, particularly the advancement of PRP and Rec-PRP.

In its financial summary for the quarter ending September 30, 2025, Propanc reported total current assets of $17 million and a reduction in total current liabilities by $2 million. The net cash from financing activities for the quarter was $2.53 million, with a cash balance of $600,000 at quarter-end.

Management expressed optimism regarding the company’s progress. “Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” stated James Nathanielsz, CEO of Propanc. He emphasized the company’s commitment to initiating the Phase 1b PRP clinical trial, advancing Rec-PRP into preclinical development, and expanding its intellectual property portfolio.

Propanc Biopharma is committed to developing innovative solutions aimed at preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. Its lead product candidate, PRP, is designed to address the fundamental drivers of cancer proliferation and spread.

For further details, visit the company’s official website at www.propanc.com.

The statements contained within this release that are not historical facts are considered forward-looking statements, reflecting the company’s current expectations regarding its market position and product development plans. As with all forward-looking statements, these involve risks and uncertainties that could cause actual results to differ materially from those anticipated.

For investor inquiries, contact Propanc Biopharma at [email protected].